Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 5/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365836 | 0.86 | MAPT (0.49) | — | |
| SCHEMBL19670537 | 0.84 | CNR2 (0.51) | CNR2THRBRHOAFAAHCNR1 | |
| SCHEMBL19365834 | 0.84 | CNR2 (0.51) | CNR2THRBRHOAFAAHCNR1 | |
| SCHEMBL17618795 | 0.83 | CNR2 (0.49) | CNR2THRBRHOAFAAHCNR1 | |
| SCHEMBL19365388 | 0.82 | SMN1; SMN2 (0.47) | CNR2TRPV4 | |
| SCHEMBL19706075 | 0.82 | KDM1A (0.43) | FAAH | |
| SCHEMBL19365389 | 0.82 | FYN (0.44) | — | |
| SCHEMBL19365580 | 0.81 | MAPT (0.43) | TRPV4 | |
| SCHEMBL19670264 | 0.80 | MAPT (0.45) | RHOAUBE2MDCUN1D1 | |
| SCHEMBL16776332 | 0.79 | CNR2 (0.51) | CNR2THRBRHOAFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885THRB 2054/4885RHOA 4798/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885THRB 2054/4885RHOA 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.